The transition from traditional small-molecule drugs to complex biological agents—such as antimicrobial peptides (AMPs), recombinant proteins, and aptamers—is currently bottlenecked by a fundamental economic gap. While these molecules offer superior specificity and lower toxicity, their production costs often remain orders of magnitude higher than the conventional alternatives they aim to replace.
Research in this field focuses on bridging this "cost-to-scale" gap by moving away from expensive chemical synthesis and toward high-yield biological "cell factories" and streamlined purification workflows.
The Economic Barrier of Molecular Complexity
The primary challenge identified across diverse applications, from oil recovery to neurotoxic envenoming, is that the chemical synthesis of long or modified chains is prohibitively expensive. Marlon H. Cardoso and Osmar Nascimento Silva highlight that while synthetic peptides like Pa-MAP 1.9 show high efficacy against drug-resistant bacteria, their manufacturing costs create a significant barrier to widespread clinical adoption compared to traditional small-molecule antibiotics.
This disparity is not limited to medicine. In industrial materials, Linyou Cao and colleagues note that specialized engineered proteins face similar hurdles when competing with petroleum-based polymers. Whether the goal is a medical dressing as described by Yaqi Sun or a bone-inducing implant surface developed by Hyeong‐Cheol Yang, the financial burden of producing the biochemical agent at a commercial scale remains the primary obstacle to market entry.
Engineering High-Yield Cell Factories
To achieve price parity, researchers are shifting production from the chemistry lab to biological systems. The goal is to treat microorganisms as autonomous manufacturing plants.
Ya Hao and Jianhua Wang have demonstrated that recombinant expression systems, particularly those using the yeast Pichia pastoris, can achieve yields exceeding one gram per liter. This threshold is critical; it represents the point where biological fermentation becomes economically competitive with chemical synthesis. For instance, Yuefeng Wang successfully used this yeast-based approach to mass-produce recombinant human collagen, overcoming the safety and scalability issues inherent in extracting collagen from animal tissues.
Beyond microbes, "molecular farming" in plants offers another path to scale. Yunpeng Wang and colleagues have explored using tobacco chloroplasts to express human neurotrophic factors, bypassing the high operational costs and technical complexities of mammalian cell cultures.
Streamlining the Downstream Pipeline
Producing a molecule inside a cell is only half the battle; the "downstream" process of extracting and purifying that molecule often accounts for the majority of the final cost. Traditional methods rely on expensive chromatography or specialized enzymes for site-specific cleavage, which Liangjun Zheng identifies as a major cost driver.
To solve this, researchers are developing non-chromatographic purification methods. Zheng and his team utilized a specialized fusion tag (DAMP4) combined with simple acid cleavage to achieve 96% purity of the antimicrobial peptide Kiadin. This approach removes the need for expensive resins and enzymes, providing a blueprint for low-cost, high-volume manufacturing. Similarly, Yuchen Han suggests that finding cheaper alternatives for protein immobilization, such as using anchor peptides on plastic surfaces, is essential for scaling discovery and production pipelines.
Small-Molecule Mimicry as an Alternative
When the cost of producing a large protein remains too high, an alternative strategy is to identify small synthetic molecules that can mimic the biological function of the larger protein.
Ji Heon Rhim illustrates this by identifying small-molecule compounds that can replace expensive recombinant proteins in the differentiation of human neural progenitor cells. By using these synthetic alternatives, researchers can achieve the same therapeutic result—such as generating dopamine neurons for Parkinson's research—at a fraction of the cost and with greater stability. This "mimicry" approach effectively sidesteps the bio-manufacturing bottleneck by returning to the established, low-cost infrastructure of traditional pharmaceutical chemistry.